Find the best CNRS technologies to boost your innovative project.
30.01.2020
11827-01
06.11.2018
Materials – Coating 07293-01
06.11.2018
Materials – Coating 10581-01
06.11.2018
Chemistry / Environment 08758-01
06.11.2018
11127-01
06.11.2018
Environment and Energy 11107-01
We can guide you through the whole technology transfer process.
Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.
00611-01
Cancer, Cellular therapy, Gastrointestinal cancer, Adipose-derived adult stem cells, Extra-medular white adipose tissue, Pancreatic Cancer, Gastric Cancer, Colorectal Cancer
French patent application FR0604443 filed on May 18th, 2006 entitled “Utilisation de cellules derives du tissu adipeux pour la preparation d’un medicament anti-tumoral”
Pierre CORDELIER
Louis BUCAIL
Louis CASTEILLA
Béatrice COUSIN-DELARUE
Jean-Marie PERON
Exclusive or non-exclusive licenses
Laboratoire de Neurobiologie, Plasticité Tissulaire et Métabolisme Energétique, a CNRS and University of Toulouse III (UPS) laboratory (UMR 5018) in Toulouse, France.
This invention reports the use of cells derived from adipose tissue for elaboration of antitumoral treatment, in particular for gastrointestinal cancer. In this type of cancer, the effectiveness of conventional therapeutics, like surgery, chemotherapy and radiotherapy have only limited effect on survival or tumour load. Unfortunately, actual medical treatment (chemotherapy and radiation) for theses cancer does not result in many cures, and combinations of chemotherapy and radiotherapy are only allowing patients to live longer and have a better quality of life. In this domain there is a lack of effective therapy, especially in advanced cancer when the surgery is not possible any more.
The inventor presents a new alternative by using cellular therapy. Cells from the vascular stroma fraction of extra-medular white adipose tissue, called ADAS (for adipose-derived adult stem cells) are able to slow down the development of tumour.
This invention reports the use of cells derived from adipose tissue for elaboration of antitumoral treatment, in particular for gastrointestinal cancer. In this type of cancer, the effectiveness of conventional therapeutics, like surgery, chemotherapy and radiotherapy have only limited effect on survival or tumour load. Unfortunately, actual medical treatment (chemotherapy and radiation) for theses cancer does not result in many cures, and combinations of chemotherapy and radiotherapy are only allowing patients to live longer and have a better quality of life. In this domain there is a lack of effective therapy, especially in advanced cancer when the surgery is not possible any more.
The inventor presents a new alternative by using cellular therapy. Cells from the vascular stroma fraction of extra-medular white adipose tissue, called ADAS (for adipose-derived adult stem cells) are able to slow down the development of tumour.
The application of this invention is the development of a new cancer treatment, in particular for gastrointestinal cancer like Pancreatic Cancer, Gastric Cancer and Colorectal Cancer.
For further information, please contact us (Ref 00611-01)
24.11.2015
Health / Therapeutic 04222-01
29.09.2014
Health / Therapeutic 04216-01
24.02.2014
Health / Therapeutic, Medical Diagnostic, Research Tools And Screening 04676-01
30.01.2020
11827-01
06.11.2018
Materials – Coating 07293-01
06.11.2018
Materials – Coating 10581-01
06.11.2018
Chemistry / Environment 08758-01
06.11.2018
11127-01
06.11.2018
Environment and Energy 11107-01